BYM338

· Novartis Pharmaceuticals

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for BYM338, covering 2016-05-03 to 2020-12-17. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis [Phase 2]